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Abstract
Interferons are key modulators of the immune system, and are central to the control of many diseases. The response of
immune cells to stimuli in complex populations is the product of direct and indirect effects, and of homotypic and
heterotypic cell interactions. Dissecting the global transcriptional profiles of immune cell populations may provide insights
into this regulatory interplay. The host transcriptional response may also be useful in discriminating between disease states,
and in understanding pathophysiology. The transcriptional programs of cell populations in health therefore provide a
paradigm for deconvoluting disease-associated gene expression profiles. We used human cDNA microarrays to (1) compare
the gene expression programs in human peripheral blood mononuclear cells (PBMCs) elicited by 6 major mediators of the
immune response: interferons a, b, v and c, IL12 and TNFa; and (2) characterize the transcriptional responses of purified
immune cell populations (CD4
+ and CD8
+ T cells, B cells, NK cells and monocytes) to IFNc stimulation. We defined a highly
stereotyped response to type I interferons, while responses to IFNc and IL12 were largely restricted to a subset of type
I interferon-inducible genes. TNFa stimulation resulted in a distinct pattern of gene expression. Cell type-specific
transcriptional programs were identified, highlighting the pronounced response of monocytes to IFNc, and emergent
properties associated with IFN-mediated activation of mixed cell populations. This information provides a detailed view of
cellular activation by immune mediators, and contributes an interpretive framework for the definition of host immune
responses in a variety of disease settings.
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Introduction
Interferons are a class of cytokines first identified in 1957 as
having a protective effect against viral infection [1]. Interferons
can be divided into three groups; type I (IFNa/b/e/k/v) that
engage the IFNAR1/2 receptor, type II (IFNc, the sole member)
that signal through the IFNGR1/2 receptor [2], and type III
(IFNl) that utilize IFN-lR1 and IL-10R2 receptors [3,4].
The type I interferons, IFNa (of which there are 13 subtypes),
IFNb and IFNv are secreted by most cell types in response to viral
infection [5]. Mice lacking intact interferon receptors are highly
susceptible to viral infection [6]. Type I IFN stimulation induces a
number of different systems involved in the activation of the
immune response, cell growth and the control of apoptosis, in
addition to the PKR (dsRNA-dependent protein kinase), 2-5A
synthetase and Mx antiviral systems [7,8]. Type I interferon
subtypes have also been reported to have distinct activities [9,10];
these IFN subtype-specific effects are influenced by factors such as
receptor binding efficiencies [11], constitutive levels of IFN
expression [12], and the specific viral-target cell combination
[13]. By contrast type II interferon (IFNc), secreted by activated
NK cells and T lymphocytes, has been implicated primarily in the
activation of macrophages and has been demonstrated to be
important for the protection of the host against intracellular
pathogens such as Leishmania, Toxoplasma and Mycobacterium species
[14]. Mutations in the IFNc receptor have been associated with
increased susceptibility to mycobacterial infection [15]. Interferons
are involved in a wide range of clinically important phenomena,
ranging from activation of immune responses to infection [14] to
cancer suppression [16] to depression [17]. Recombinant
interferon therapy has been approved for a spectrum of conditions
such as hepatitis B and C infections, Kaposi’s sarcoma, multiple
sclerosis and chronic granulomatous disease [5].
DNA microarray analysis of gene expression has enabled the
description and discrimination of disease states [18–21]; and
presents an opportunity for both diagnostic and prognostic marker
discovery [22–24]. IFN signatures have been identified as
prominent aspects of many transcriptional profiles [25–28].
However, to interpret these gene expression patterns further, a
basic understanding of the response of complex cell populations to
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previously to investigate the global effects of interferon stimulation
in human non-immune cells after 6 h incubation in a fibrosarcoma
cell line [29], in murine fibroblast cells [30], in primary endothelial
cells after 18 h treatment [31], and in epithelial cells using ChIP-
chip technology to investigate STAT1/STAT2 binding events
[32]. An increased understanding of the temporal and cell-specific
nature of gene expression in response to cytokine stimulation may
reveal insights into the activation and interactions of different cell
types during infection.
In this study we used human cDNA microarrays (1) to compare
the responses of a mixed population of immune cells (human
peripheral blood mononuclear cells) to stimulation with 6 major
mediators of immune activation – the human type I interferons
(IFNa, b and v), type II interferon (IFNc), and two factors
involved in cell-mediated immunity (IL12 and TNFa); and (2) to
contrast the transcriptional reorganization of purified immune cell
populations (CD4
+ and CD8
+ T cells, B cells, NK cells and
monocytes) to treatment with IFNc. This gene expression analysis
of both mixed and purified immune cell populations sampled over
time allowed both cytokine-specific and cell-specific transcriptional
patterns to be identified. This information may assist in the
recognition of host immune responses in disease settings, help to
reveal novel immuno-modulatory actions of pathogens during
infection, and offers a global view of cellular activation after
exposure to a variety of cytokines.
Results
PBMC cytokine activation profiles
To investigate the temporal program of gene expression in a
physiologically relevant mixed cell population specific to activators
of innate immunity, we treated PBMCs with recombinant
IFNa2b, IFNb1a, IFNv, IFNc, IL12 and TNFa and sampled at
intervals of 0.5, 1, 4, 8, 12, and 24 h post stimulation.
Differentially expressed genes were identified using the Signifi-
cance Analysis of Microarrays (SAM) algorithm to compare the
temporal response of each treatment with a mock time course
(treatment with 0.1% BSA/PBS), as well as to all other treatments.
The temporal expression pattern of 1857 genes found to be
significantly differentially expressed (FDR,1%, minimum of 2
fold change) are shown in Figure 1. Tables 1 and 2 detail the
numbers of genes differentially expressed by each treatment
relative to the mock time series. The magnitude of differences in
transcript abundance, and the correlations between responses to
each pair of stimuli are detailed further in Tables S1 and S2. No
significant changes were detected by flow cytometry in the
proportion of major cellular subsets in PBMCs over the 24 h
time period, confirming that differences in gene transcript
abundance were due to changes in transcript abundance and
not to shifting demographies of PBMC sub-populations.
The human immune cells were treated with cytokines at a
standardized concentration of 0.6 pM, in order to facilitate
comparisons among the cytokine activation profiles; the use of units
(U) was undesirable in this setting as these values are calculated with
biological assays, and are based on different parameters for each
cytokine. However, the influence of cytokine concentration on the
pattern of transcription was addressed in an additional experiment,
in which PBMCs were treated with 0.006, 0.6 and 60 pM of
recombinant IFNc (corresponding to 1, 100 and 10,000 U IFNc,
respectively) and sampled at 0.5, 1, 2, 4, 8 and 12 h post stimulation
(Figure S1). The qualitative transcriptional responses were similar for
the three IFNc concentrations, but the amplitude of the responses
increased with IFNc dose. The subset of genes differentially induced
by type I, as opposed to type II IFN, was not induced even at the
highest tested concentrations of IFNc; suggesting that the differential
responses of PBMCs to type I and type II interferons cannot be
explained by a difference in effective dose.
A common stereotyped response to type I IFNs
A common activation profile of 201 genes (Table S3) was
induced in a stereotyped temporal pattern by the type I interferons
(significantly more highly expressed by IFNa, IFNb and IFNv
treatment compared to mock); the consistency of this response is
reflected by the high correlation scores between type I IFN
treatments (Table S1). The similarity between gene expression
responses to IFNv and IFNa/b confirms that these interferons
trigger similar physiological events, and are likely to signal through
the same type I interferon receptor [7]. Genes encoding proteins
implicated in the major antiviral pathways initiated by interferon
stimulation were consistently induced, including the dsRNA-
dependent protein kinase pathway (PRKRA, EIF2AK2 (PRKR),
PALM2-AKA1, EIF2B1), the 2-5A synthetase system (OAS1/2/
3), and the Mx pathway (MX1/2). Genes involved in the control
of apoptosis were also highly expressed after type I IFN treatment
(CASP1/5/10, FAS, FASLG, FAF1, GADD45B, BAG1). Type I
interferon stimulation also led to increases in transcripts encoding
a range of immune cell surface receptors - CD4, CD38, CD69,
CD2AP, IL15RA, IL8RB, LEPR, MSR1, TLR3, TLR7,
TNFRSF11A, TRD. The induction of TLR3 (recognizing
dsRNA) and TLR7 (recognizing ssRNA) suggests enhanced
vigilance against viral infection activated by type I IFNs
(MYD88 was also up-regulated). The stimulation of human
PBMCs with type I IFNs also induced a number of genes
encoding soluble factors such as the chemokines, CCL7, CCL8,
CCL13, CXCL9 (MIG), CXCL10 (IP10), CXCL11 and the
interleukins, IL6 and IL15. Genes encoding components of the
IFN signaling pathways, including the transcriptional mediators
STAT1 and STAT2, the Janus activated kinase JAK2, and the
negative regulator of JAK-STAT signaling SOCS1 (SSI-1) [33]
were consistently highly expressed; together with a number of
genes encoding transcription factors ATF3/5, IRF2/7, IFI16,
SP100/110, SPIB, TFDP2. Numerous transcripts encoding
proteins whose roles remain to be fully characterized were also
significantly induced G1P2, G1P3 (6–16), IFI27, IFI35, IFI44,
IFIT1/5, IFITM1 (9–27), IFITM2/3, IFRD1, IFRG28, ISG20, as
previously described [14].
Type I vs. type II IFN programs
IFNc signals through a different specific receptor and has
biological effects distinct from those of the type I interferons in vitro
and in vivo [34]. The transcriptional response of PBMCs to IFNc
stimulation in the initial 24 h appears largely to be restricted to a
subset of type I IFN-inducible genes (Figure 1). This statement
must be qualified with the observation that transcripts of IFNc
itself were induced within the first 4 h of type I IFN treatment
(Figure 2), which may result in the initiation of an IFNc
transcriptional program in type I IFN-treated cells. IFNa has also
been demonstrated to promote the proliferation of IFNc-secreting
T cells [35].
We identified 114 genes that were significantly more highly
induced by all type I IFNs than by IFNc treatment, and 10 genes
that were more highly induced by IFNc stimulation (in a direct
comparison between type I and II IFN responses, Table S4). As
expected, genes associated with the anti-viral PKR, 2-5A synthetase
and Mx pathways were more highly induced by type I IFNs,
correlating with the greater antiviral potency of type I compared to
type II IFNs [5]. The interferon regulatory factors IRF2 and IRF7,
Leukocyte Interferon Responses
PLoS ONE | www.plosone.org 2 March 2010 | Volume 5 | Issue 3 | e9753and the transcription factors ATF3, ELF1, IFI16, KLF6, OLIG2,
SP100, SP110, and SPIB were also consistently more highly
expressed by type I than by type II IFNs. The 10 genes more highly
induced by IFNc than by type I IFN treatment included FCGR1A
which encodes a high affinity Fc receptor, the IL6 receptor (IL6R),
the chemokine CXCL9, the macrophage lectin (CLECSF14),
ubiquitin D (UBD), the transcriptional enhancer C/EBPa and the
MHC class II regulator MHC2TA (CIITA). MHC2TA has
previously been noted to be induced to a greater degree by IFNc
treatment than by type I IFN treatment [14].
Figure 1. PBMC transcriptional programs elicited by cytokine exposure. The PBMC response to stimulation with 0.6 pM IFNa, b, v, c, IL12
and TNFa from 30 minutes to 24 h after treatment. 1857 genes were identified to be significantly differentially expressed in response to one or more
stimuli compared to mock-treated PBMC (0.1% BSA/PBS). The expression profiles are ordered by hierarchical clustering; the genes are displayed as
rows, time points/conditions as columns, in temporal order (see yellow key). Red coloring signifies the up-regulation of expression; blue coloring
denotes down-regulation. Samples were taken at time intervals of 0.5, 1, 4, 8, 12 and 24 h. The column marked SAM indicates (in red) which genes
were identified to be significantly differentially expressed in response to each cytokine.
doi:10.1371/journal.pone.0009753.g001
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IL12
Stimulation with IFNc resulted in the induction of 111 genes,
including the chemokines CCL8, CXCL9, CXCL10 and
CXCL11 and the interleukins IL1A, IL7 and IL15, together with
the cell surface receptors CCR5, CD38, CSF2RB, FCGR1A,
ICAM, IL15RA, MSR1, NKTR, P2RY13, SLAMF1. IFNc
stimulation also induced several factors involved in the comple-
ment system (BF, C1QB, C4A and SERPING1). Additionally,
genes implicated in the metabolism of tryptophan (INDO, WARS)
and MHC class I processing (PSMB9, TAP1/2) were highly
expressed after treatment with both type I and type II IFNs. The
transcriptional response of PBMCs to IL12 stimulation was similar
to the IFNc activation program, as evidenced by the high
correlation score and small number of differentially expressed
genes that distinguished these two treatments (Table S1).
Interestingly the transcriptional response to IL12 appeared to be
delayed by approximately 4 h when compared to the response to
IFNc (Figure 1). IFNc-induced genes were significantly enriched
in the subset of genes up-regulated by IL12 (hypergeometric p
value =5.6610
24). Transcripts of IFNc were significantly induced
by IL12 treatment (Figure 2), as were IFNc levels in the culture
medium (data not shown). The delayed IFNc-like response
following IL12 treatment may therefore be due to the transcrip-
tional induction and subsequent release of IFNc from IL12-
activated T cells in the mixed cellular population of PBMCs. The
similarity in PBMC gene expression patterns resulting from IFNc
or IL12 stimulation may also reflect the induction of analogous
pathways involved in macrophage activation, and explain why
polymorphisms in IFNc and IL12-related genes often result in
similar pathological conditions [15,36].
Transcriptional signature of TNFa
The response to TNFa was strikingly different from all of the
IFN response programs (Figure 1). The 130 genes induced by
TNFa treatment of PBMCs encode cytokines and chemokines
implicated in the orchestration of the inflammatory response
(CCL15/20/23, CCL3L1, CXCL1/2/3, IL16, IL18, IL1A, IL1B,
IL6, IL8, SLAMF1, TNF), and a number of genes involved in
NFKB activation and its regulation (IKBKG, NFKB1, NFKB2,
NFKBIA, NFKBIZ, RELB, TNFAIP2/3, TNFRSF11A, TRAF1).
The gene ontology terms associated with this group were
significantly enriched for functional categories such as cytokine
activity, response to external stimulus, and NFKB signaling. In
addition, functional groups involved in chemotaxis, and the
regulation of cell proliferation or apoptosis were also associated
with the genes induced by TNFa treatment. The activation of the
NFKB pathway is a well-established consequence of TNFa
ligation [37,38], and was not associated with the gene ontology
terms linked to IFN stimulation.
Cell-type associated gene expression
To determine which cell types present in PBMCs contributed to
the IFNc signature described above, and to investigate whether
discrete subpopulations of immune cells respond in the same way
to stimuli as do mixed populations, CD4+ T cells, CD8+ T cells, B
cells, NK cells and monocytes were each isolated from human
PBMCs and then stimulated with IFNc. The reliability of this cell
separation and microarray analysis strategy was confirmed by
comparing the gene expression profiles of the unstimulated cell
subsets (time zero and 0.1% BSA/PBS treated time points). Genes
were defined as cell type-associated if they were identified (by
multiple SAM two class pair wise comparisons, FDR,1%,
minimum of 2 fold change) as significantly more highly expressed
in a single cell type when compared to all other cell subsets
(Figure 3a). Through this procedure, 179 genes were determined
to be B cell associated, 210 genes were T cell associated (with 17
CD4+ and 25 CD8+ associated genes); 161 genes were NK cell
associated and 1042 were monocyte associated (Table S5). The
expression of known cell type-specific genes (such as CD4, 8, 14,
19 and HLA molecules) was restricted to the appropriate purified
cell subset. In addition, the match between the B cell and T cell
specific genes found here and in a previously published study was
highly significant (hypergeometric probability 5.68610–149, and
5.87610–74 respectively) [39].
Cell-type specific IFNc responses
To investigate the immune cell specificity of activation
programs induced by a major component of cell-mediated
Table 1. PBMC transcriptional responses to 0.6 pM IFNa, b, v,
and c, IL12 and TNFa.
IFNa IFNb IFNv IFNc IL12 TNFa
Induced 226 370 288 111 57 130
Repressed 31 114 89 77 53 125
Numbers of genes are indicated. Differentially expressed genes were identified
by SAM as significantly more highly expressed or under-expressed relative to
mock treated time series.
doi:10.1371/journal.pone.0009753.t001
Table 2. PBMC common type I IFN transcriptional program,
and common IFNc and IL12 program.
Stereotyped type I
IFN response
IFNc-IL12
response
Induced 201 35
Repressed 17 35
Numbers of genes are indicated. Differentially expressed genes were identified
by SAM as significantly more highly expressed or under-expressed relative to
mock treated time series.
doi:10.1371/journal.pone.0009753.t002
Figure 2. Induction of IFNc in PBMCs after IL12 exposure. The
mean expression profile of IFNc transcripts after exposure of PBMCs to
0.6 pM IFNa, b, v, and c, IL12 and TNFa; as determined by microarray
analysis at time intervals of 0.5, 1, 4, 8, 12 and 24 h post stimulation.
Standard deviations are indicated with error bars.
doi:10.1371/journal.pone.0009753.g002
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0.6 pM (100 U) IFNc was measured at 0.5, 1, 4, 8, 12 and 24 h.
Significantly induced genes were identified by comparing each
time series to a parallel unstimulated mock time course of the same
purified cell type (FDR,1%, minimum of 2 fold change). 80 genes
were significantly up-regulated in B cells by IFNc stimulation, 36
in CD4+ T cells, 21 in CD8+ T cells, 17 in NK cells and 294 in the
purified monocyte population (Figure 3b and Table S6). Six genes
were significantly induced in all cell types (B, T, NK lymphocytes
and monocytes): those encoding the chemokine CXCL10
(SCYB10); the complement regulatory peptidase inhibitor SERP-
ING1; the suppressor of cytokine signaling SOCS1 (SSI-1);
ribosomal protein RPS9; the niacin receptor 2 HM74 (NIACR2);
and the high affinity Fc receptor FCGR1A (CD64). The
transcriptional activators STAT1 and IRF1 were significantly
induced in CD4+ and CD8+ T cells, B cells and monocytes; while
ISGF3G (interferon-stimulated transcription factor 3 gamma,
IRF9) was found to be significantly up-regulated in only CD4+ T
cells. Genes coding for the MHC class II proteins HLA-DRA, B1,
B5 and HLA-DQA1 were highly expressed in CD4+ cells.
Expression of class II MHC has been previously demonstrated
in non-professional antigen-presenting cells after IFNc stimulation,
and in activated T cells [40]. The B cell response to IFNc included
the induction of genes encoding CD38 and CD69, both of which
have been implicated in B cell activation and maturation, and a
number of genes involved in MHC class I presentation such as the
proteasome subunits (PSMB8 and B9, PSME1 and 2) and TAP1
and 2 transporters. Interestingly, neither STAT1 nor IRF1 were
significantly induced as part of the limited transcriptional response
of purified NK cells to IFNc.
As expected, monocytes had the greatest response to IFNc
stimulation; activation of macrophages is a well-defined role of
IFNc. Of the 294 genes that were induced by IFNc (61 of which
were identified to be monocyte-associated), over 40 coded for cell
Figure 3. Cell-type associated gene expression. A (left). Cell type-associated genes identified from the transcriptional profiles of unstimulated
isolated cell types (time zero and 0.1% BSA/PBS-treated time series). Genes were defined as cell type-associated if they were identified as significantly
more highly expressed in a single cell type compared to all other cell types. The expression profiles are ordered by hierarchical clustering; the genes
are displayed as rows, cell type/time points as columns. Red coloring signifies high expression; blue coloring denotes low expression. Cell type-
associated gene clusters are marked. B (right). The cell type-specific nature of IFNc transcriptional responses. Purified subsets of B cells, CD4
+ T cells,
CD8
+ T cells, NK cells and monocytes were stimulated with 0.6 pM IFNc and sampled at 0.5, 1, 4, 8, 12 and 24 h. 807 significantly induced genes were
identified, and ordered by cell type and hierarchical clustering. The genes are displayed as rows, time points/cell subsets as columns. Red coloring
signifies up-regulation, and blue coloring signifies down-regulation of expression after IFNc exposure relative to the mock-treated discrete cell
population. The column marked SAM indicates (in red) which genes were significantly differentially expressed by IFNc in each cell type. Genes of
interest are marked as annotated in Source [73].
doi:10.1371/journal.pone.0009753.g003
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(CCRL2, CRLF1, CSF2RB, HM74, IL15RA, IL2RA, IL6R,
IL8RB), the cell activation markers (CD36, CD38, CD69, CD97),
and a number of proteins involved in cellular adhesion (CD226,
EVA1, ICAM1, ITGAL, ITGA4, ITGB7, LGALS3BP, MUC1,
SIAT1). The up-regulation of numerous genes involved in MHC
class I and II expression (TAP1 and 2, TAPBP, MHC2TA, RFX5,
HLA-DMA/B, HLA-DNA, HLA-DPB1), proteasome formation
(PSMA2, 4, and 5, PSMB8, 9, and 10, PSME1 and 2) and protein
turnover (specifically ubiquitination - UBD, UBE2E2, UBE2L6,
UBE3A, USP25, LOC51619) underscores the role of IFNc in
promoting antigen processing and presentation in monocytes. The
major mediators of IFNc-induced signaling, STAT1, JAK2, and
IRF1, were induced together with several factors that may regulate
STAT and JAK function (CISH, NMI, PTPRC, PTPRO,
SOCS1) [34]. IFNc stimulation also resulted in the increased
expression of an additional 32 proteins predicted to regulate
transcription, including C/EBPa, EGR2, HLX1, IFI16, IRF8,
KLF2 and 4, STAT2, SP110 and the MHC II regulatory elements
MHC2TA and RFX5. In a complementary approach, putative
C/EBP, EGR, HOX, IRF, ISRE, MEF and STAT transcription
factor binding sites were amongst 104 motifs identified after
searching 4000 nt either side of the start sites of the 294 genes
induced by IFNc treatment in the purified monocyte population.
The integration of temporal patterns of gene expression with
transcription factor motif mining tools promises to reveal novel
regulatory networks affecting immune cell function [41].
Temporal response to IFNc
The temporal response of the monocyte population to IFNc
treatment was analyzed by partitioning the differentially expressed
genes into 7 significantly represented expression profiles using Short
Time-series Expression Miner (STEM) [42] (Figure 4a, detailed in
Table S7). Correlating the temporal pattern of monocyte gene
expression with the enriched functional categories of genes may
help to elucidate the timing of events following monocyte
activation. For example, the functional category for the proteasome
complex was highlighted in profiles of induced genes with peak
transcript abundance at 4 h and 8 h after IFNc treatment
(Figure 4a, profiles D and E); perhaps reflecting a time-delayed
transcriptional response after signaling cascades were triggered by
IFNc receptor cross-linking. The GO ontology terms for
chemotaxis (and taxis) were significantly enriched in the subset of
genes repressed after IFNc stimulation (Figure 4a, profile G); which
may be an indicator of monocyte activation and differentiation.
Most interestingly, the functional category associated with
negative regulators of cellular or biological processes was
significantly enriched among genes induced within 1 h of IFNc
treatment (Figure 4a, profiles A–C). 15 genes shared this gene
ontology term, including BCL6 (a zinc finger transcriptional
repressor) [43], and two suppressors of cytokine signaling, SOCS1
a pseudosubstrate inhibitor of JAK-STAT signaling [44], and
CISH (CIS/SOCS) an inhibitor of growth hormone signaling
through STAT5b [45]. The up-regulation of CISH together with
the significant enrichment of genes containing STAT5 binding
motifs induced within 1 h of IFNc stimulation (Figure 4a, profiles
A–C) predicts that monocyte activation is likely to be partially
mediated through STAT5 (even though STAT5 itself was not
identified in this analysis as significantly differentially expressed).
RHOH, a repressor of Rac GTPase-mediated signaling (specifi-
cally RAC1) [46], was also induced immediately after IFNc
treatment; conversely, RAC1 was repressed with time (Figure 4a,
profile G). RHOH has recently been demonstrated to down-
regulate leukotriene production in neutrophils [47], and may
therefore fulfill a similar negative feedback function during
monocyte activation. Tristetraprolin (TTP, ZFP36), induced
within 1 h by IFNc (Figure 4a, profile A), has been implicated
in the rapid degradation of IFNc and IL2 mRNA [48] and may
therefore play an important role in constraining the monocytic
pro-inflammatory response. Other interactions that may temper
the activation state of monocytes after IFNc stimulation include
the repression of pro-inflammatory ligand receptors, IFNc
receptor 1 (IFNGR1, although this was not identified by the
significance testing algorithm), the IL1 receptor 1 (IL1R1) [49],
and chemokine receptor (CXCR4). The induction of CISH and
RHOH and the repression of IFNGR1 in monocytes after IFNc
exposure were confirmed by quantitative RT-PCR, as was the
modest induction of STAT5A (Figure S2).
By modeling the monocyte response over time, possible signaling
cascades could be recognized; for example, the generation of MHC
class II molecules is dependent on the expression of the class II
transactivator CIITA (MHC2TA) that is in turn induced by IRF-1
[50]. This pathway, resulting in MHC class II molecule expression
after IFNc stimulation, can be followed through the time series with
the induction of IRF-1 within minutes of IFNc treatment (Figure 4a,
profile C), followed by the up-regulation of CIITA peaking at 4 h
(Figure 4a, profile D), and then the steady induction of MHC class II
genes (HLA-DMA, DMB, DOA, DPB1, Figure 4a, profile F). In an
example of negative regulation, the subset of genes repressed after
IFNc treatment (Figure 4a, profile G) was significantly enriched for
AP-1 binding sites. This (together with the down-regulation of FOS
itself) may reflect the action of BCL6, a transcriptional repressor that
has been demonstrated to block AP-1 activity [43], which is induced
w i t hap e a ka t1ha f t e rI F N c stimulation (Figure 4a, profile B). The
complexity of potential crosstalk following monocyte stimulation by
IFNc is summarized in Figure 4b; where the previously characterized
interactions (identified in the ResNet 6 Mammalian database)
downstream of IFNc are mapped onto the genes identified in this
study to be differentially expressed by IFNc treatment. Proteins
whose expression is altered by IFNc, that may also have a regulatory
effect on IFNc expression itself, are highlighted in yellow.
Transcriptional plasticity of immune cells to stimulation
This transcriptional analysis of immune cell subtype responses
to IFNc treatment allowed us to investigate the effect of immune
stimulation on the expression of cell-associated signatures. The
changing RNA abundance profiles of these cell type-associated
genes were revealed by comparing the cell type-associated gene
expression signatures (Figure 3a, Table S5) with the cell subset
responses to IFNc stimulation (Figure 3b, Table S6). 79 genes,
identified as cell type-associated in unstimulated discrete popula-
tions, were recognized to be induced by IFNc treatment in a
different cell subtype population (Figure 5). After IFNc stimula-
tion, these genes were no longer expressed in a cell type-specific
manner; moreover, these genes were not necessarily IFNc-
inducible in their associated cell type. The term transcriptional
plasticity has been adopted in this setting to describe the regulation
of cell type-associated genes in other cell subsets after stimulation.
For example, MHC Class II (HLA-DMB/DNA/DQA1, TAP2)
and immunoglobulin genes (CD79B, IGHM) associated with B
cell gene expression were induced after stimulation in other cell
types; of these genes, only TAP2 was induced by IFNc treatment
in the discrete B cell population. The transcriptional flexibility of
immune cells following stimulation, with the differential expression
of cell type-associated genes in distinct isolated cell populations,
suggests a plasticity of the cellular immune response that deserves
further attention.
Leukocyte Interferon Responses
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populations
The overlapping transcriptional signatures of cells stimulated
with IFNs is both cell subset- and IFN-specific; for example,
STAT2, an important mediator of type I interferon signaling, was
induced by IFNc treatment only in the purified monocyte cell
population, as were an additional 22 genes induced by type I IFNs,
compared to IFNc stimulation in PBMCs (Table S4). We did not
detect changes in relative abundance of transcripts in the IFNc-
treated PBMCs for many of the genes whose transcripts were
detected as induced by IFNc in the purified monocyte population,
which was possibly a reflection of the dilution of monocyte-specific
transcripts in the total PBMC cellular RNA population. More
interestingly, 40 genes (including CCR5, CD83/86, GOS2,
INHBA, IRF4, OAS1/3, CCL2/3/4/7, SELPLG and TNFAIP6,
Table S8) that were significantly induced by IFNc in the
heterogeneous population comprising PBMCs were not detected
as induced to a significant degree in any of the purified cell subsets.
15 of these genes were identified to be part of the TNFa activation
program (Figure 1) and 22 genes were monocyte-associated
(Figure 3a), suggesting that monocytes may respond to additional
interactions within the heterogeneous PBMC population. This
rudimentary analysis highlights the emergent physiology of a
tissue, in this case, peripheral blood, comprising a mixture of
communicating cells.
Discussion
We characterized the differential effects of 6 cytokines on gene
expression in a mixed population of human immune cells; defining
for the first time the conserved transcriptional response to IFNv,
together with IFNa and b, and revealing major similarities in
IFNc and IL12 transcriptional programs. We and many others
have examined gene expression profiles in peripheral blood in vivo
and ex vivo in order to identify both gene expression signatures and
specific regulatory pathways activated in health-associated ho-
meostasis and in disease. Data derived from carefully controlled
experiments establishing the transcriptional response to specific
stimuli in relevant cell populations have become an important part
of the framework used to interpret patterns of gene expression
observed in these complex studies. The response to interferons has
gained a prominent central role in the study of many immune
processes. We have observed an interferon-response gene
expression signature associated with shock in dengue infection
[26], with early pre-clinical responses to Ebola [51], with the
response of leukocytes to Neisseria meningitidis [52], and with a
pattern of gene expression that discriminates Kawasaki Disease
and acute adenovirus infection [53]. The detailed description of
the shared and unique features of the transcriptional programs of
the cytokines used in this study, and of the contribution of
individual cell types to the gene expression patterns observed in a
mixed cell population constitutes a valuable resource that has
facilitated our analysis of these previously-published data sets, and
will enable researchers to better delineate regulatory networks,
elucidate pathways that are disrupted during disease, and
deconvolute gene expression patterns in cell populations exposed
to multiple complex stimuli.
Other groups have examined the response to interferons in non-
immune cell populations. Many of the observations of Der et al.
[29] who investigated the expression profiles of HT1080 cells (a
human fibrosarcoma cell line) after 6 h stimulation with
interferons IFNa, b, and c by microarray analysis, were confirmed
in this study. A core set of established IFN-regulated genes were
identified by both analyses; however, there are subsets of genes
that appear to be induced differentially in these two studies. This
may be due to technical differences such as concentration of
interferons, microarray platform and gene annotation, but may
also reflect cell-specific (professional immune vs non-immune)
responses to IFN stimulation [54]. It is also possible that
differences reflect donor-to-donor variation in interferon-mediated
responses. However, the overall similarity in findings, in addition
to the results from studies investigating inter-individual variation in
gene expression patterns, indicate that the stimulus rather than a
donor-specific background is likely to be the primary feature
driving transcriptional responses of peripheral blood immune cell
populations [22,55–57]. Similarly, comparison of our results with
those from studies of IFNc stimulation of primary endothelial cells
and HT1080 cells [31,58] revealed broad concordance, with a few
exceptions. A recent study by Indraccolo et al. [59] identified 41
genes to be more highly induced by IFNa compared to IFNc in
human umbilical vein endothelial cells; as in our study, the
majority of these genes were predicted to be involved in antiviral
responses. Six genes were induced to a greater degree by IFNc
than by IFNa; of these, CXCL9 (MIG) and ubiquitin D (UBD or
FAT10), both of which are involved in targeting proteins for
proteasomal degradation [60], were also identified in the present
study. Therefore, the chemokine, CXCL9, and UBD, which is a
marker of immune activation in hepatocellular carcinoma and
colon carcinoma [61], are preferentially induced by type II
interferon in both professional immune and non-immune cells.
A parallel analysis of IFNc responses of isolated subsets of the
cells comprising the PBMC pool allowed us to begin dissecting the
contribution of specific cells in this complex tissue. The
transcriptional response to IFNc in T cell, B cell and NK cellular
populations was limited in comparison to the large number of
genes induced in purified monocytes, where RHOH and CISH
are predicted to have novel regulatory roles in controlling
monocyte activation. These transcript abundance datasets may
be utilized in combination to examine which particular cell types
are responding to specific stimuli in dynamic scenarios. For
Figure 4. Monocyte responses to IFNc. A (top). The temporal transcriptional responses of monocytes to IFNc stimulation. Of 363 genes that
were significantly differentially expressed following treatment with 0.6 pM IFNc, 264 genes were assigned to 7 significantly represented expression
profiles, A–G. The temporal response (measured in mean fold change) of the genes assigned to each cluster is plotted at 0.5, 1, 4, 8, 12 and 24 h post
treatment. Clusters A (square), B (triangle) and C (diamond) colored red; D (triangle) and E (square) in green; F (square) in purple; and G (square) in
blue. B (bottom). A network of predicted crosstalk downstream of IFNc exposure. Previously characterized interactions between IFNc and the 363
genes identified as differentially expressed after IFNc treatment in monocytes were mapped. The expression of 109 genes were predicted to be
directly affected by IFNc. Secondary regulatory events were characterized by the expression of 65 additional genes (identified to be differentially
expressed by IFNc treatment) whose expression was modified by those 109 genes but not by IFNc directly. This network illustrates the complexity of
possible interplay downstream of IFNc stimulation. In addition, 61 proteins reported to have an effect on IFNc expression itself are highlighted in
yellow, and may represent positive and negative feedback loops mediating cell activation. Gene identifiers are colored by temporal expression
pattern after IFNc treatment as detailed in Figure 4A (dark red (profiles A–C), lighter red (D and E), pink (F), blue (G), grey (unassigned)). Gene
identifiers are also shaped by putative function, transcription factors (ellipse), kinase/phosphatases (triangle), ligands (rhombus), receptors (cross). The
nature of the interactions are indicated with connecting lines either reflecting a positive (green), negative (blue), or undefined (grey) impact on
downstream gene or protein expression.
doi:10.1371/journal.pone.0009753.g004
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PLoS ONE | www.plosone.org 9 March 2010 | Volume 5 | Issue 3 | e9753example, the transcription factors C/EBPa, involved in myeloid
cell differentiation [62] and associated with acute myeloid
leukemias [63], and MHC2TA (CIITA), the major regulator
controlling expression of MHC class II molecules [50], were both
preferentially induced by type II IFN (in PBMCs compared to type
I IFNs and TNFa). These genes were also up-regulated with time
in the monocyte population alone (in response to IFNc treatment),
suggesting that the expression of these major mediators of cell
activation in a complex model of infection may be due primarily to
the response of monocytes to IFNc. This study also highlighted the
plasticity of the cellular transcriptional response to stimulation,
with the induction of ostensibly cell type-specific genes in
alternative cell types after treatment with IFNc. Comparison of
the expression patterns derived from mixed and purified immune
cell populations after IFNc treatment illuminated differences in the
way in which cells responded to a stimulus in isolation versus a
complex environment, with a number of genes only induced by
IFNc stimulation in complex cellular populations. The immune
response to pathogens requires the coordinated interaction of
multiple cells, and the presence of different cell populations; thus,
the cross-talk between populations may be more representative of
in vivo functioning than are the findings from isolated cell
populations. Further investigation into these interactions may
provide novel insights into cellular activation and complex
responses measured from mixed populations.
The focus of this study has been on the defined actions of
cytokines in the activation of the immune system. While infection
is one setting in which these actions may be relevant, these data
may also help to elucidate additional functional roles of
interferons, such as in tumor suppression. Exploration of the
transcriptional programs initiated by interferons in heterogenous
and homogenous cell populations, extends our understanding of
the global actions of these major mediators of inflammation,
improving our comprehension of disease states, immune cell
signaling cascades, the immunomodulatory mechanisms of
infectious agents and potential recombinant therapies.
Materials and Methods
PBMC extraction and cell subset isolation
Human primary peripheral blood mononuclear cells (PBMCs)
were purified from whole blood of healthy donors using Ficoll-
Paque PLUS (GE Healthcare) according to manufacturer’s
instructions. To control for genetic variation [64], PBMCs were
extracted from a single healthy donor for the cytokine comparison
and dose response experiments. For the cell subset isolations where
larger quantities of PBMCs were required, PBMCs were purified
from buffy coat extractions from three healthy donors supplied by
the Stanford University Blood Center. PBMC cell subsets (CD4
+
and CD8
+ T cells, B cells, NK cells and monocytes) were purified
by negative selection using antibody-coated magnetic bead
separation (Invitrogen) following the manufacturer’s instructions.
The cell subsets were isolated by negative rather than positive
selection, as the consequences of cross-linking cell surface selection
markers used in positive selection (CD2, CD3, CD4, CD8, CD19,
CD14) on the activation state of the purified cell populations
before stimulation are unknown. Cell subset purity was assessed by
flow cytometry, and determined to be 67–98%.
Cell stimulation
PBMCs and individual cell subsets were incubated at 1.5–
2.0610
6 cells/well in RPMI 1640 medium supplemented with
10% heat-inactivated fetal calf serum and 2 mM L-glutamine
(Invitrogen) at 37uC, 5% CO2 for 24 h before stimulation. Cells
were treated with 0.6 pM recombinant IFNa2b, IFNb1a, IFNc,
IFNv, IL12, or TNFa (R&D Systems), and sampled at time
intervals from 0.5 h to 24 h after stimulation. Additionally, cells
were treated with 0.1% BSA/PBS alone and used for untreated
(mock) control time courses. As reference points for these time
series, multiple replicates of untreated cells were sampled at time 0
(5 PBMC time zeros for the cytokine comparison, 4 PBMC time
zeros for the dose response study, and 3 time zeros for each
purified cell subset).
RNA extraction and amplification
Total RNA was extracted in TRIzol LS (Invitrogen) followed by
standard chloroform purification and isopropanol precipitation.
RNA was re-suspended in RNase-free water, quantitated with a
NanoDrop ND-1000 spectrophotometer (NanoDrop Technolo-
gies) and stored at 280uC. 500 ng total RNA was amplified using
the MessageAmp modified Eberwine linear amplification proce-
dure (Applied Biosystems). All samples to be compared were
extracted and amplified together.
Microarray analysis and data processing
4 mg amplified RNA was labeled with Cy5-dUTP (GE
Healthcare) and combined with 3 mg of Cy3-labelled reference
cDNA derived from a pool of RNA from a panel of 11 human cell
lines (Stratagene Universal Human Reference RNA). The samples
were washed and concentrated using MinElute columns (Qiagen)
and competitively hybridized once to custom printed cDNA
microarrays containing 37,632 elements from cDNA clones
representing approximately 18,000 unique human genes (as
previously described [18]). The hybridized slides were scanned
using a GenePix 4000A microarray scanner (Axon Instruments).
Comparative spot intensities were calculated from the images, and
areas of poor quality excluded from further analysis using GenePix
Pro 6.0 (Axon Instruments). The datasets discussed in this
publication have been deposited in the Stanford Microarray
Database [65], and NCBI’s Gene Expression Omnibus [66] and
are accessible through GEO Series accession number GSE17762
[67]. Analysis was restricted to cDNA elements with a regression
correlation of .0.6, fluorescence intensities of .2.5 fold signal/
background in Cy3 or Cy5 channels and a minimum signal
intensity of .100 in both channels for at least 80% of the arrays.
The expression ratios were normalized for array variation, and the
Figure 5. The transcriptional plasticity of immune cellular responses to IFNc stimulation. 79 genes associated with a single isolated
immune cell subtype (without stimulation) were induced after IFNc treatment in other cell types. Genes defined as cell type-associated (by
comparing unstimulated time series, as detailed in Figure 3A) are marked on the left. The top panel detailing B cell associated genes, followed by T
cell, NK cell, and monocyte associated genes illustrated in the bottom panel. The differential regulation of these genes after IFNc treatment in each
cell type (as in Figure 3B) is described on the right. The expression profiles are ordered by hierarchical clustering; the genes are displayed as rows, cell
type/time points as columns. Red coloring in the cell-type associated panels (on left) signifies highly expressed in a single cell type compared to all
other cell types; blue coloring denotes low expression. Red coloring in the IFNc responsive panels (on right) signifies up-regulation, and blue coloring
signifies down-regulation of expression after IFNc exposure relative to the mock-treated discrete cell population. B (B cells); T4 (CD4
+ T cells); T8
(CD8
+ T cells); NK (NK cells); M (monocytes). The column marked SAM details (in red) which genes were significantly differentially expressed by IFNc in
each cell type. Genes are marked as annotated in Source [73].
doi:10.1371/journal.pone.0009753.g005
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macro (C. Liu, Stanford University) to the study-specific time zeros
(average of 5 biological replicates for the cytokine comparison, 4
for the dose response study, and 3 for each purified cell subset).
Time zero replicate expression profiles were highly similar with
average r
2 values .0.95. The statistical package SAM (Signifi-
cance Analysis of Microarrays, version 1.15) was used to identify
genes significantly differentially expressed in the normalized data
sets by pair wise comparison with a minimum 2 fold cutoff at a
false discovery rate of ,1% of the median [68]. The transformed
datasets were then hierarchically clustered using Cluster 2.11 and
the results displayed using Treeview 1.60 [69]. The hypergeo-
metric function was used to determine the significance of
overlapping gene lists. Short Time-series Expression Miner
(STEM) [42] was used to identify significantly represented
temporal expression profiles (p,0.05 after Bonferroni multiple
testing correction). The Database for Annotation, Visualization
and Integrated Discovery (DAVID) [70,71] allowed significantly
enriched functional classifications of genes to be recognized.
Transcription factor binding motif searching was performed using
TFSearch after sequences were prepared using EZRetrieve and
RepeatMasker [72]. The monocyte temporal response to IFNc
treatment was explored using Ariadne Pathway Studio 6.2 (ResNet
6 Q1 2009 Mammalian database, derived in part through text
mining) mapping downstream expression and promoter binding
interactions. Significantly differentially expressed genes are
presented in Tables S1, S2, S3, S4, S5, S6, S7, S8.
Quantitative RT-PCR
cDNA was synthesized from total RNA using an anchored
oligo(dT)20 primer (Invitrogen) and Superscript III RT (Invitrogen),
in accordance with the manufacturer’s instructions. PCRs were
prepared using the TaqMan Universal PCR Master Mix (Applied
Biosystems), and cDNA derived from 10 ng total RNA. Relative
abundance of the target transcripts was calculated by comparison
to a standard curve, and normalized to the expression level of
ribosomal protein L5 (RPL5). Applied Biosystems (ABI) assay IDs
are as follows: CISH Hs01003603_m1; IFNGR1 Hs00988304_
m1; RHOH Hs00180265_m1; RPL5 Hs00851991_u1; STAT5A
Hs00559643_m1.
Flow cytometry
The cellular composition of PBMCs and the purity of isolated
PBMC cell subsets were determined by flow cytometry using a BD
LSRII flow cytometer (BD Biosciences). A five color assay for CD4
(pacific blue, Molecular Probes), CD8 (FITC), CD56 (PE), CD19
(PerCP-Cy5.5), CD14 (APC-Cy7) (all BD Biosciences unless
otherwise stated) was performed on cells extracted and labeled
according to manufacturer’s recommendations. Results were
captured and analyzed using the BD FACSDiva software (BD
Biosciences). The induction of apoptosis was estimated at 24 or
48 h after treatment using the Annexin V-FITC/propidium iodide
detection assay (BD Biosciences).
Supporting Information
Figure S1 The transcriptional profile of PBMCs stimulated with
one of three concentrations of IFNc. 370 genes were significantly
induced by IFNc treatment, as assessed at 0.5, 1, 2, 4, 8 and 12 h
after exposure to 0.006 pM, 0.6 pM or 60 pM IFNc (correspond-
ing to 1, 100 or 10,000 U, respectively). The expression profiles
are ordered by hierarchical clustering; the genes are displayed as
rows, time points/IFNc dose as columns. Red coloring signifies the
up-regulation of expression relative to T0. The column marked S
indicates (in red) which genes were significantly induced by each
concentration of IFNc.
Found at: doi:10.1371/journal.pone.0009753.s001 (2.37 MB TIF)
Figure S2 Quantitative RT-PCR validation. Confirmation of
the differential regulation of CISH, RHOH, IFNGR1 and
STAT5A in monocytes after stimulation with IFNc. Fold change
is detailed relative to the untreated monocyte profile at 0.5, 1, 4, 8,
12 and 24 h. Relative abundance of the target transcripts was
calculated by comparison to a standard curve, and normalized to
the expression level of ribosomal protein L5 (RPL5). Standard
deviations, calculated from triplicate samples, are marked with
error bars. The corresponding transcriptional patterns of these
genes derived from microarray analysis are displayed in Figure 4.
Found at: doi:10.1371/journal.pone.0009753.s002 (0.55 MB TIF)
Table S1 A matrix describing the differential gene expression of
PBMCs stimulated with each cytokine. The top half of the table
lists the number of genes identified by SAM as significantly more
highly expressed (numerator) or under-expressed (denominator) in
each comparison (y axis vs. x axis) after exposure to 0.6 pM IFNa,
b, v, and c, IL12 and TNFa. The bottom half of the matrix
provides the mean correlation score (from 6 time points sampled)
of the PBMC responses to each treatment compared to all other
stimuli; standard deviations are marked in italics.
Found at: doi:10.1371/journal.pone.0009753.s003 (0.03 MB
DOC)
Table S2 PBMC cytokine activation profiles. The PBMC
responses to stimulation with 0.6 pM IFNa, b, v, and c, IL12
and TNFa from 30 minutes to 24 h after treatment. Genes
identified by SAM analysis (minimum 2 fold cutoff at a false
discovery rate of ,1% of the median) are identified for each
cytokine compared to mock (0.1% BSA/PBS) treated PBMCs.
The genes are partitioned into induced/repressed lists for each
cytokine, together with mean fold expression ratios, and are
ordered alphabetically using gene annotation from Source [70].
Data are summarized in Figure 1 and Table 1.
Found at: doi:10.1371/journal.pone.0009753.s004 (0.18 MB
XLS)
Table S3 Common response to type I interferon. 201 genes
were induced after 0.6 pM treatment with IFNa, b and IFNv
compared to mock (0.1% BSA/PBS) treated PBMCs. Genes
identified by SAM analysis (minimum 2 fold cutoff at a false
discovery rate of ,1% of the median). Gene fold induction is
detailed for each IFN treatment. Data are summarized in Figure 1
and Table 1.
Found at: doi:10.1371/journal.pone.0009753.s005 (0.05 MB
XLS)
Table S4 Genes identified to be preferentially expressed by type
I or type II interferons.
Found at: doi:10.1371/journal.pone.0009753.s006 (0.11 MB
DOC)
Table S5 Cell-type associated genes. Genes were defined as cell
type-associated if they were identified (by multiple SAM two class
pairwise comparisons, FDR,1%, minimum of 2 fold change) as
significantly more highly expressed in a single (unstimulated) cell
type compared to all other (unstimulated) cell type gene expression
profiles. Data are summarized in Figure 3a.
Found at: doi:10.1371/journal.pone.0009753.s007 (0.20 MB
XLS)
Table S6 The cell type-specific nature of IFNc transcriptional
programs. Purified subsets of CD4
+ T cells, CD8
+ T cells, B cells,
NK cells and monocytes were stimulated with 0.6 pM IFNc and
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(determined using the SAM algorithm, minimum 2 fold cutoff at a
false discovery rate of ,1% of the median) by IFNc are indicated
for each purified cell subset together with mean fold expression
ratios. The genes are ordered alphabetically, using gene
annotation from Source [70]. Data are depicted in Figure 3b.
Found at: doi:10.1371/journal.pone.0009753.s008 (0.08 MB
XLS)
Table S7 The temporal transcriptional response of monocytes to
0.6 pM IFNc. The significantly differentially expressed genes
(determined using the SAM algorithm, minimum 2 fold cutoff at a
false discovery rate of ,1% of the median), and sampled at 0.5, 1,
4, 8, 12 and 24 h post IFNc treatment, were separated into 7
significantly represented profiles using STEM. The table is
ordered by STEM profile (as illustrated in Figure 4a), then
alphabetically using gene annotation from Source [70].
Found at: doi:10.1371/journal.pone.0009753.s009 (0.07 MB
XLS)
Table S8 IFNc-induced transcripts unique to mixed-cell popu-
lations. 40 genes significantly induced by IFNc in the heteroge-
neous PBMC population that were not significantly induced after
IFNc treatment in any of the purified cell subsets. The genes are
ordered alphabetically using gene annotation from Source [70].
Found at: doi:10.1371/journal.pone.0009753.s010 (0.02 MB
XLS)
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